Page 23 - PHESGO (PERTUZUMAB-TRASTUZUMAB) - Product Monograph

37. De Cock E, Pivot X, Hauser N, et al. A time and motion study of subcutaneous versus intravenous trastuzumab
in patients with HER2-positive early breast cancer. Cancer Med. 2016;5(3):389-397. doi:10.1002/cam4.573
38. R Tan, S-A Im, A Mattar, et al.Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous
injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label,
multicentre, non-inferiority, phase 3 study Lancet Oncol (2020)
39. PHESGO. Local UAE PI
40. Mylonas 2017
41. Lopez-Vivanco, 2017
42. De Cock, 2013
43. PHranceSCa, CSR
44. Scheuer W, Friess T, Burtscher H, et al. Strongly enhanced antitumor activity of trastuzumab and pertuzumab
combination treatment on HER2-positive human xenograft tumor models. Cancer Res.2009;69(24):9330-9336.
45. Lee-Hoeflich ST, Crocker L, Yao E, et al. A central role for HER3 in HER2-amplified breast cancer: implications
for targeted therapy. Cancer Res. 2008;68(14):5878-5887
46. FeDeriCa primary CSR WO40324
47. O’Shaughnessy J, Sousa S, Cruz J, et al. Patient (pt) preference and satisfaction with the subcutaneous
fixed-dose combination of pertuzumab (P) and trastuzumab (H) in pts with HER2-positive early breast cancer
(HER2+ eBC): interim analysis of the open-label randomised cross-over
48. Oshuagnessy J, etal ESMO 2020
49. Pivot, X., Gligorov, J., Müller, V., Barrett-Lee, P., Verma, S., Knoop, A., Curigliano, G., Semiglazov, V., López-Vivanco,
G., Jenkins, V., et al. (2013). Preference for subcutaneous or intravenous administration of trastuzumab in
patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. The Lancet
Oncology, 14(10), 962-970.
50. Baselga J, Cortés J, Kim S-B, et al; CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel for
metastatic breast cancer. N Engl J Med. 2012;366(2):109-119.

M-AE-00000086 23